Lonza Significantly Expands US Presence

(MENAFN- Swissinfo) The Swiss life sciences group Lonza is significantly expanding its presence in the United States. It is acquiring five plants from the German Merck Group. This content was published on November 3, 2026 - 10:03 2 minutes Keystone-SDA

Deutsch de Lonza baut Pharmaauftragsproduktion in den USA stark aus Original Read more: Lonza baut Pharmaauftragsproduktion in den USA star

With this transaction, the pharmaceutical supplier is doubling its US presence from four to nine CDMO sites, the company announced on Tuesday. CDMO stands for contract development and manufacturing organisation and refers to contract development and manufacturing for pharmaceutical companies.

The company emphasises that the US is the largest market for innovative pharmaceutical products. The acquired network supports customers from the clinical phase through to commercial launch in promising growth areas.

According to the announcement, around 1,100 employees are moving to Lonza, bringing the total number of staff in the US to more than 6,000. The purchase price is based on a company valuation in the low to mid three-digit millions in Swiss francs.

More More Drug pricing Pharma pushes for higher European drug prices, Trump or no Trump

This content was published on Oct 21, 2026 Pharmaceutical firms are still pressing Europe, including Switzerland, to raise drug prices despite limits to Trump's Most-Favoured Nation plan.

Read more: Pharma pushes for higher European drug prices, Trump or no

MENAFN03112026000210011054ID1111910555